PLoS ONE · 2017 · 38 citations · 24 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DeliveryPharmacokinetics Of Anticancer AgentsLung Cancer PharmacotherapyMultiple MyelomaPharmacokinetics Of Anticancer DrugsAnticancer ActivityAnticancer ChemotherapyMicellesMultiple Myeloma TherapyPolymer MicellesPolymeric MicellesProteasome Inhibitor TherapyProteasome Inhibitors
Carfilzomib (CFZ) is a peptide epoxyketone proteasome inhibitor approved for the treatment of multiple myeloma (MM). Despite the remarkable efficacy of CFZ against MM, the clinical trials in patients with solid cancers yielded rather disappointing results with minimal clinical benefits. Rapid degradation of CFZ in vivo and its poor penetration to tumor sites are considered to be major factors limiting its efficacy against solid cancers. We previously reported that polymer micelles (PMs) composed of biodegradable block copolymers poly(ethylene glycol) (PEG) and poly(caprolactone) (PCL) can improve the metabolic stability of CFZ in vitro. Here, we prepared the CFZ-loaded PM, PEG-PCL-deoxycholic acid (CFZ-PM) and assessed its in vivo anticancer efficacy and pharmacokinetic profiles. Despite in vitro metabolic protection of CFZ, CFZ-PM did not display in vivo anticancer efficacy in mice bearing human lung cancer xenograft (H460) superior to that of the clinically used cyclodextrin-based CFZ (CFZ-CD) formulation. The plasma pharmacokinetic profiles of CFZ-PM were also comparable to those of CFZ-CD and the residual tumors that persisted in xenograft mice receiving CFZ-PM displayed an incomplete proteasome inhibition. In summary, our results showed that despite its favorable in vitro performances, the current CFZ-PM formulation did not improve in vivo anticancer efficacy and accessibility of active CFZ to solid cancer tissues over CFZ-CD. Careful consideration of the current results and potential confounding factors may provide valuable insights into the future efforts to validate the potential of CFZ-based therapy for solid cancer and to develop effective CFZ delivery strategies that can be used to treat solid cancers.
24
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Horacio Cabral, Yu Matsumoto, Kazue Mizuno et al. · Nature Nanotechnology · 2011 · 2.4K citations
Pharmacy, Oncology, Pharmacokinetics +14
Targeted drug delivery to tumors: Myths, reality and possibility
You Han Bae, Kinam Park · Journal of Controlled Release · 2011 · 1.9K citations · Full text
Pharmacy, Oncology, Pharmacology +12
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Julian Adams, Vito J. Palombella, Edward A. Sausville et al. · PubMed · 1999 · 1.5K citations
Medicine, Oncology, Pharmacology +14